Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?

Kidney International, Supplement

Volumn 68, Issue 98, 2005, Pages

  Perico, Norberto ^b   Codreanu, Igor ^b   Schieppati, Arrigo ^b   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

Chronic kidney disease; Disease progression; Multidrug approach; Proteinuria; Renin angiotensin system blockade

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; PROTEIN INHIBITOR; RAMIPRIL; RAS INHIBITOR; TRANDOLAPRIL; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN RECEPTOR;

ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE; LIPID BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; METHODOLOGY; MULTICENTER STUDY; REVIEW; GLYCEMIC CONTROL; INCIDENCE; RISK REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES; RECEPTORS, ANGIOTENSIN; REMISSION INDUCTION; RENIN-ANGIOTENSIN SYSTEM;

EID: 33644588876     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09804.x     Document Type: Article

References (24)

1. XUE J, MA J, LOUIS T, COLLINS A: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12:2753-2758, 2001
2. LYSAGHT M: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13:S37-S40, 2002
3. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
4. REMUZZI G, RUGGENENTI P, PERICO N: Chronic renal diseases: Renal protective benefits of renin-angiotensin system inhibition. Ann Intern Med 136:604-615, 2002
5. ZOJA C, BENIGNI A, REMUZZI G: Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens 13:31-37, 2004
6. REMUZZI A, GAGLIARDINI E, DONADONI C, et al: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 62:885-894, 2002
7. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
8. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352:1252-1256, 1998
9. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
10. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
11. PARVING H-H, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
12. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
13. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
14. TAAL MW, BRENNER BM: Combination of ACEi and ARB therapy: Additional benefit in renoprotection? Curr Opin Nephrol Hypertens 11:377-381, 2002
15. RUGGENENTI P: Angiotensin-converting enzyme inhibition and angiotensin II antagonism, in nondiabetic chronic nephropathies. Semin Nephrol 24:158-167, 2004
16. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 361:117-124, 2003
17. CAMPBELL R, SANGALLI F, PERTICUCCI E, et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63:1094-1103, 2003
18. RUGGENENTI P, SCHIEPPATI A, REMUZZI G: Progression, remission, regression of chronic renal diseases. Lancet 357:1601-1608, 2001
19. ORTH SR, STOCKMANN A, CONRADT C, et al: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 54:926-931, 1998
20. GAEDE P, VEDEL P, LARSEN N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
21. RUGGENENTI P, BRENNER BM, REMUZZI G: Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 88:254-259, 2001
22. FIORETTO P, STEFFES MW, SUTHERLAND DE, et al: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998
23. PERICO N, AMUCHASTEGUI CS COLOSIO V, et al: Evidence that an angiotensin converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5:1139-1146, 1994
24. BENEDICT GROUP: The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT). Control Clin Trials 24:442-461, 2003